Rising number of fertility clinics worldwide, technological advancements, and increasing public-private investments, funds, and grants. However, the high procedural costs of assisted reproductive technology procedures in developed markets and unsupportive government regulations for certain infertility treatment options are expected to limit market growth to a certain extent. 

Significant rise in number of fertility clinics, coupled with the decline in the fertility rate across the globe. Along with this growing focus of players and government towards the launching and acquiring new fertility centers across the globe is likely to contribute towards the growth of the segment. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43497112 

The fertility rate worldwide is declining steadily owing to various factors, such as the growing trend of late marriages and increasing age-related infertility. Global fertility rates are projected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050.  

Along with fertility surgeries, thousands of cycles of ART procedures such as in vitro fertilization (IVF) are performed every year globally. The cost of IVF treatment varies from country to country due to the lack of reimbursement policies. 

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the infertility treatment market. The infertility treatment market in Asia and other emerging countries is characterized by the growing focus on healthcare infrastructural improvements.  

To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments agreements/partnerships with regional/domestic players, geographical expansions, and acquisitions.to increase their presence in these markets and tap a large number of customers. 

Prominent players in infertility treatment market are The Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher Scientific, Inc. (US), FUJIFILM Irvine Scientific (US), Kitazato Corporation (Japan), and Hamilton Thorne Ltd. (US).